OneDigital Investment Advisors LLC Increases Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

OneDigital Investment Advisors LLC increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 379.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,149 shares of the medical research company's stock after buying an additional 2,492 shares during the period. OneDigital Investment Advisors LLC's holdings in Bio-Rad Laboratories were worth $1,034,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Venturi Wealth Management LLC grew its stake in Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after purchasing an additional 87 shares in the last quarter. GeoWealth Management LLC lifted its stake in Bio-Rad Laboratories by 342.9% during the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock valued at $31,000 after acquiring an additional 72 shares during the period. Picton Mahoney Asset Management lifted its position in Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock valued at $32,000 after purchasing an additional 35 shares during the period. Asset Planning Inc acquired a new stake in Bio-Rad Laboratories during the fourth quarter worth about $33,000. Finally, UMB Bank n.a. increased its holdings in shares of Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BIO has been the subject of several recent analyst reports. Royal Bank of Canada restated an "outperform" rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Wells Fargo & Company decreased their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $380.20.

Bio-Rad Laboratories Price Performance

BIO stock traded down $3.47 during mid-day trading on Thursday, reaching $240.61. The company's stock had a trading volume of 69,382 shares, compared to its average volume of 311,874. The stock has a market cap of $6.74 billion, a PE ratio of -3.70 and a beta of 1.12. The company's 50 day moving average is $248.55 and its two-hundred day moving average is $306.55. Bio-Rad Laboratories, Inc. has a fifty-two week low of $215.38 and a fifty-two week high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.